What question did this study set out to answer?

This research aims to evaluate how effectively drugs permeate the blood brain barrier (BBB) to reach tumors and assess their cytotoxicity in glioma models.

May 15, 2026Open Access

A perfused, parallelized blood brain barrier-tumor platform for compound permeation and efficacy investigations

WWWei Wu WeiETH Zurich MSMartin StanoETH Zurich BKBettina KritzerUniversity Children's Hospital Zurich

Puntos clave

This research aims to evaluate how effectively drugs permeate the blood brain barrier (BBB) to reach tumors and assess their cytotoxicity in glioma models.
Developed a scalable BBB-tumor model to simulate drug interactions.
Tested drug delivery and efficacy in vitro with glioma cell models.
Measured cytotoxicity and BBB disruption at varying drug concentrations.
The in vitro BBB reduced drug delivery to tumors, hindering efficacy.
Drug-induced disruption of the BBB occurred at sub-toxic doses, enhancing drug permeation.
Distinct cytotoxic responses were observed across different cell models, supporting the need for personalized therapy.

Resumen

drug concentrations for the BBB. Our results demonstrate that the in vitro BBB significantly limited drug delivery to the tumor, thereby limiting drug efficacy. Furthermore, drug-induced BBB disruption occurred at sub-toxic doses, which led to increased drug permeation to the glioma models. Finally, cell-model-specific responses revealed distinct cytotoxicity behavior, demonstrating the importance of personalized therapy testing. Our scalable BBB-tumor platform provides a physiologically relevant in vitro model system to assess drug permeation, cytotoxicity, and tumor-BBB interactions and offers the potential to advance the discovery of new effective therapeutics against neurological diseases.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo